Suchergebnisse - "XKJ5VVK2WD"

PubPharm (435)

1

BCL-2 Modulates IRE1α Activation to Attenuate Endoplasmic Reticulum Stress and Pulmonary Fibrosis

enthalten in: American journal of respiratory cell and molecular biology | 2024

von Le Saux, C. | Ho, T. | Brumwell, A. | +8

CommentIn: Am J Respir Cell Mol Biol. 2024 Apr;70(4):231-232. - PMID 38259233

2

AMPK inhibition sensitizes acute leukemia cells to BH3 mimetic-induced cell death

enthalten in: Cell death and differentiation | 2024

von Jia, J. | Ji, W. | Saliba, A. | +19

3

Senolysis of gemcitabine-induced senescent human pancreatic cancer cells

enthalten in: Cancer reports (Hoboken, N.J.) | 2024

von Hoque, M. | Iida, Y. | Kotani, H. | +1

4

Senolytic-facilitated Reversal of End-Organ Dysfunction in a Murine Model of Obstructive Sleep Apnea

enthalten in: American journal of respiratory and critical care medicine | 2024

von Badran, M. | Puech, C. | Khalyfa, A. | +4

CommentIn: Am J Respir Crit Care Med. 2024 Apr 15;209(8):907-908. - PMID 38301230

5

The Differential Effect of Senolytics on SASP Cytokine Secretion and Regulation of EMT by CAFs

enthalten in: International journal of molecular sciences | 2024

von Bogdanova, D. | Kolosova, E. | Pukhalskaia, T. | +3

6

PROTAC-Mediated Dual Degradation of BCL-xL and BCL-2 Is a Highly Effective Therapeutic Strategy in Small-Cell Lung Cancer

enthalten in: Cells | 2024

von Khan, S. | Cao, L. | Wiegand, J. | +5

UpdateOf: bioRxiv. 2024 Mar 01;:. - PMID 38464204

7

OGDH and Bcl-xL loss causes synthetic lethality in glioblastoma

enthalten in: JCI insight | 2024

von Nguyen, T. | Torrini, C. | Shang, E. | +11

8

Combination of navitoclax (Bcl-2 and Bcl-xL inhibitor) and Debio-0932 (Hsp90 inhibitor) suppresses the viability of prostate cancer cells via induction of apoptotic signaling pathway

enthalten in: Medical oncology (Northwood, London, England) | 2024

von Asdemir, A. | Özgür, A.

9

Dual targeting Bcl-2 and Bcl-xL augments osteosarcoma response to doxorubicin

enthalten in: Journal of chemotherapy (Florence, Italy) | 2024

von Cao, C. | Pei, Y. | Yu, H. | +1

10

Phase 1 trial of navitoclax and sorafenib in patients with relapsed or refractory solid tumors with hepatocellular carcinoma expansion cohort

enthalten in: Investigational new drugs | 2024

von Emiloju, O. | Yin, J. | Koubek, E. | +19

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[44]